Navigation Links
Prolong's Large Scale Manufacturing of Sickle Cell Product to be Headed by Industry Veteran
Date:12/15/2011

SOUTH PLAINFIELD, N.J., Dec. 15, 2011 /PRNewswire/ -- Prolong Pharmaceuticals today announced that Tom Flachmeyer has joined Prolong to spearhead the firms' engineering and facilities planning function for it oxygen therapeutic product SANGUINATE™.   Having previously directed the construction of the world's largest biotech facility to date, Wyeth's Grange Castle facility in Dublin, Ireland, Flachmeyer is charged with expanding Prolong's current cGMP production facility to support worldwide clinical development in sickle cell patients.

Tom brings an extensive background in managing technical organizations, strategic / capital planning and capital project execution and has a proven track record of executing technically complex projects. Formerly a Director of Project Management at Parsons, Life Sciences Group, Tom has held senior management positions in Engineering at Wyeth, Warner-Lambert (now Pfizer) and Foster Wheeler.  At Schering Plough he spent 5 years in Ireland and 3 years in Singapore executing large scale capital projects that delivered critical capabilities to the supply chain.

"Tom's international experience in designing high quality, large scale bio-manufacturing facilities to FDA approved status, is unparalleled in the industry," said Glenn Kazo, Prolong's President. "As lead project manager for several multinational engineering firms, and with direct experience as a bio-pharma company executive, Tom is ideally suited to drive our expansion." 

About Prolong Pharmaceuticals
Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing biopharmaceutical products targeting the treatment of anemia resulting from an oxygen deficiency. First founded in 2002 as a research company Prolong is focused on sickle cell anemia, diabetic ischemia, and several trauma indications. The company's senior management team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for more than $30 billion in drug sales worldwide. For more information visit: www.prolongpharmaceuticals.com.

 


'/>"/>
SOURCE Prolong Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
2. Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Ion Channel Targets, Booth 5
5. Neptune Krill Oil, NKO(R), enters WALGREENS, the largest U.S. retail pharmacy chain, under the brand name Schiff(R) MegaRed(TM)
6. New carbon material shows promise of storing large quantities of renewable electrical energy
7. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
8. SAFC Pharma Completes Large-Scale API Manufacturing Expansion in Ireland
9. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
10. Complete Genomics Launches, Becomes Worlds First Large-Scale Human Genome Sequencing Company
11. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):